Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$1.68 -0.6%	$1.67	$1.43 ▼ $4.98	$168.69M	1.62	165,990 shs	41,106 shs
FULC Fulcrum Therapeutics	$6.90 +8.7%	$4.24	$2.32 ▼ $10.13	$372.46M	2.29	970,384 shs	997,784 shs
NRIX Nurix Therapeutics	$10.04 +2.8%	$10.45	$8.18 ▼ $29.56	$765.41M	2.23	873,150 shs	551,689 shs
VNDA Vanda Pharmaceuticals	$4.31 -0.5%	$4.33	$3.81 ▼ $6.75	$254.01M	0.69	711,843 shs	193,485 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	0.00%	-3.43%	+3.05%	-32.94%	-52.26%
FULC Fulcrum Therapeutics	-1.40%	-2.46%	+79.89%	+91.27%	-11.93%
NRIX Nurix Therapeutics	+0.51%	-3.65%	-15.48%	-42.73%	-35.60%
VNDA Vanda Pharmaceuticals	0.00%	-2.48%	+1.88%	-8.07%	-17.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACIU AC Immune	2.3429 of 5 stars	3.5	2.0	0.0	2.7	0.8	1.3
FULC Fulcrum Therapeutics	0.5161 of 5 stars	1.2	1.0	0.0	2.7	2.5	0.0
NRIX Nurix Therapeutics	1.8234 of 5 stars	4.4	0.0	0.0	2.3	0.8	0.0
VNDA Vanda Pharmaceuticals	4.5536 of 5 stars	3.8	1.0	4.2	4.1	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	3.00	Buy	$10.00	495.24% Upside
FULC Fulcrum Therapeutics	2.43	Hold	$5.83	-15.46% Downside
NRIX Nurix Therapeutics	2.84	Moderate Buy	$30.44	203.23% Upside
VNDA Vanda Pharmaceuticals	3.50	Strong Buy	$16.50	282.83% Upside

Current Analyst Ratings Breakdown

Latest ACIU, NRIX, VNDA, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/14/2025	VNDA Vanda Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$13.00
5/13/2025	VNDA Vanda Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/7/2025	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/1/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00
4/29/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
4/9/2025	NRIX Nurix Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $25.00
4/9/2025	NRIX Nurix Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $35.00
4/9/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$28.30M	5.96	N/A	N/A	$2.12 per share	0.79
FULC Fulcrum Therapeutics	$80M	4.66	N/A	N/A	$3.80 per share	1.82
NRIX Nurix Therapeutics	$56.42M	13.57	N/A	N/A	$7.44 per share	1.35
VNDA Vanda Pharmaceuticals	$201.35M	1.26	N/A	N/A	$9.23 per share	0.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$60.41M	-$0.58	N/A	N/A	N/A	N/A	-28.26%	-18.98%	8/5/2025 (Estimated)
FULC Fulcrum Therapeutics	-$97.33M	-$0.07	N/A	N/A	N/A	N/A	-7.31%	-6.74%	7/30/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.80	N/A	N/A	N/A	-354.85%	-53.65%	-38.59%	7/10/2025 (Estimated)
VNDA Vanda Pharmaceuticals	-$18.90M	-$0.75	N/A	N/A	N/A	-9.51%	-3.49%	-2.90%	7/30/2025 (Estimated)

Latest ACIU, NRIX, VNDA, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	VNDA Vanda Pharmaceuticals	-$0.55	-$0.50	+$0.05	-$0.50	$45.13 million	$50.04 million
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
4/30/2025	Q1 2025	ACIU AC Immune	-$0.22	-$0.21	+$0.01	-$0.21	$1.99 million	$1.12 million
4/8/2025	Q1 2025	NRIX Nurix Therapeutics	-$0.72	-$0.67	+$0.05	-$0.67	$12.78 million	$18.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	N/A	1.86	1.86
FULC Fulcrum Therapeutics	N/A	18.44	18.44
NRIX Nurix Therapeutics	N/A	6.46	6.46
VNDA Vanda Pharmaceuticals	N/A	4.39	4.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
FULC Fulcrum Therapeutics	89.83%
NRIX Nurix Therapeutics	N/A
VNDA Vanda Pharmaceuticals	88.14%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
FULC Fulcrum Therapeutics	7.00%
NRIX Nurix Therapeutics	7.40%
VNDA Vanda Pharmaceuticals	10.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	100.41 million	94.39 million	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	51.73 million	Optionable
NRIX Nurix Therapeutics	300	76.24 million	70.42 million	Optionable
VNDA Vanda Pharmaceuticals	290	58.93 million	53.13 million	Optionable

ACIU, NRIX, VNDA, and FULC Headlines

Recent News About These Companies

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

May 27 at 9:00 AM | prnewswire.com

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by Lazard Asset Management LLC

May 26 at 3:42 AM | marketbeat.com

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by D. E. Shaw & Co. Inc.

May 25 at 3:36 AM | marketbeat.com

Insider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Acquires 10,000 Shares of Stock

May 22, 2025 | insidertrades.com

Krensavage Asset Management LLC Cuts Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

May 22, 2025 | marketbeat.com

Insider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Purchases 20,000 Shares of Stock

May 20, 2025 | insidertrades.com

Insider Buying: Mihael Polymeropoulos Acquires 20,000 Shares of Vanda Pharmaceuticals Inc (VNDA)

May 20, 2025 | gurufocus.com

HC Wainwright Issues Pessimistic Estimate for VNDA Earnings

May 18, 2025 | marketbeat.com

Jacobs Levy Equity Management Inc. Has $2.26 Million Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

May 18, 2025 | marketbeat.com

Q2 EPS Forecast for Vanda Pharmaceuticals Cut by Analyst

May 18, 2025 | americanbankingnews.com

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit ...

May 16, 2025 | gurufocus.com

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

May 16, 2025 | prnewswire.com

Vanda Pharmaceuticals (VNDA) Receives Overweight Rating from Cantor Fitzgerald | VNDA Stock News

May 14, 2025 | gurufocus.com

Vanda Pharmaceuticals (VNDA) Projected to Transform with Overweight Rating | VNDA Stock News

May 14, 2025 | gurufocus.com

Bridgeway Capital Management LLC Has $796,000 Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

May 14, 2025 | marketbeat.com

VNDA FY2025 EPS Estimate Lowered by Cantor Fitzgerald

May 13, 2025 | marketbeat.com

Dimensional Fund Advisors LP Grows Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

May 12, 2025 | marketbeat.com

Schonfeld Strategic Advisors LLC Acquires New Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

May 10, 2025 | marketbeat.com

HC Wainwright Reaffirms "Buy" Rating for Vanda Pharmaceuticals (NASDAQ:VNDA)

May 9, 2025 | marketbeat.com

Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

May 9, 2025 | finanznachrichten.de

Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges

May 8, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU, NRIX, VNDA, and FULC Company Descriptions

AC Immune NASDAQ:ACIU

$1.68 -0.01 (-0.59%)

Closing price 04:00 PM Eastern

Extended Trading

$1.72 +0.04 (+2.32%)

As of 04:49 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Fulcrum Therapeutics NASDAQ:FULC

$6.90 +0.55 (+8.66%)

Closing price 04:00 PM Eastern

Extended Trading

$7.42 +0.52 (+7.54%)

As of 07:37 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Nurix Therapeutics NASDAQ:NRIX

$10.04 +0.27 (+2.76%)

Closing price 04:00 PM Eastern

Extended Trading

$10.21 +0.17 (+1.73%)

As of 07:27 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Vanda Pharmaceuticals NASDAQ:VNDA

$4.31 -0.02 (-0.46%)

Closing price 04:00 PM Eastern

Extended Trading

$4.32 +0.02 (+0.35%)

As of 07:36 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time